Effects of Combination Lipid Therapy on Coronary Stenosis Progression and Clinical Cardiovascular Events in Coronary Disease Patients with Metabolic Syndrome: A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS)

Documenti analoghi

• Levels of Cholesterol in Small LDL Particles Predict Atherosclerosis Progression and Incident CHD in the HDL-Atherosclerosis Treatment Study (HATS)
  di: Williams, Paul T., et al.
  Pubblicazione: (2013)
• Effects of Niacin on Glucose Levels, Coronary Stenosis Progression, and Clinical Events in Subjects With Normal Baseline Glucose Levels (<100 mg/dl): A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI During Lipid-Lowering (CPC) Study
  di: Phan, Binh An P., et al.
  Pubblicazione: (2012)
• Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS)
  di: Vittone, Francesca, et al.
  Pubblicazione: (2007)
• HDL signaling and protection against coronary artery atherosclerosis in mice
  di: Trigatti, Bernardo L, et al.
  Pubblicazione: (2016)
• Association of an HDL Apolipoproteomic Score with Coronary Atherosclerosis and Cardiovascular Death
  di: Natarajan, Pradeep, et al.
  Pubblicazione: (2019)